| Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia. | |
| | |
MedLine Citation:
|
PMID: 21460870 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in patients with non-Hodgkin's lymphoma and Hodgkin's lymphoma who underwent autologous transplantation at the Cleveland Clinic and Ohio State University. In the VP+G group, median total CD34+ cells collected were 9.34 × 10(6) per kg (range 0.97-180.89), with 42% of all patients having adequate (2 × 10(6) cells per kg) CD 34+ collection after 2 days of apheresis compared with a median in the G-CSF group of 3.83 × 10(6) per kg (range, 0.72-50.38), with only 16% patients having adequate collection after 2 days (P<0.001). tMDS/tAML occurred in 15 patients (2.3%) in the VP+G and in 12 patients (3.8%) receiving G-CSF alone. (P=0.62). Increased number of days of apheresis was associated with the risk of tMDS/tAML (hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.08-1.30, P<0.001). Priming regimen was not a significant variable for relapse-free survival or OS. The addition of etoposide significantly improves the effectiveness of mobilization at the cost of an increased incidence of neutropenic fever though with no mortalities. There is no evidence of increased incidence of tMDS/tAML in patients receiving VP+G compared with those mobilized with G-CSF alone.Bone Marrow Transplantation advance online publication, 4 April 2011; doi:10.1038/bmt.2011.73. |
| | |
Authors:
|
A Mahindra; B J Bolwell; L Rybicki; P Elder; M Kalaycio; R Dean; B Avalos; R Sobecks; S Tench; S Andresen; B Pohlman; J Sweetenham; S Devine; E Copelan |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-4-04 |
Journal Detail:
|
Title: Bone marrow transplantation Volume: - ISSN: 1476-5365 ISO Abbreviation: - Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-4-4 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8702459 Medline TA: Bone Marrow Transplant Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston, MA, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT.
Next Document: What are a patient's current chances of finding a matched unrelated donor? Twenty years' central sea...